These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Costs of exacerbations of chronic obstructive pulmonary disease in primary and secondary care in 2007--results of multicenter Polish study]. Jahnz-Rózyk K; Targowski T; From S Pol Merkur Lekarski; 2009 Mar; 26(153):208-14. PubMed ID: 19388534 [TBL] [Abstract][Full Text] [Related]
5. [Roflumilast in combination with long-acting bronchodilators in the management of patients with severe and very severe COPD. A cost-effectiveness analysis for Germany]. Nowak D; Ehlken B; Kotchie R; Wecht S; Magnussen H Dtsch Med Wochenschr; 2013 Jan; 138(4):119-25. PubMed ID: 23322425 [TBL] [Abstract][Full Text] [Related]
6. [Introduction to asthma and chronic obstructive pulmonary disease pharmacoeconomics]. Jahnz-Rózyk K Pol Merkur Lekarski; 2004 May; 16 Suppl 1():5-6, 8. PubMed ID: 15524004 [TBL] [Abstract][Full Text] [Related]
7. Using cost-effectiveness analysis to sharpen formulary decision-making: the example of tiotropium at the Veterans Affairs health care system. Onukwugha E; Mullins CD; DeLisle S Value Health; 2008; 11(5):980-8. PubMed ID: 18194405 [TBL] [Abstract][Full Text] [Related]
8. Economic aspects of antimicrobial therapy of acute exacerbations of COPD. Simoens S; Decramer M; Laekeman G Respir Med; 2007 Jan; 101(1):15-26. PubMed ID: 16650975 [TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844 [TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries. Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511 [TBL] [Abstract][Full Text] [Related]
11. Health care use and economic burden of patients with diagnosed chronic obstructive pulmonary disease in Korea. Kim C; Yoo KH; Rhee CK; Yoon HK; Kim YS; Lee SW; Oh YM; Lee SD; Lee JH; Kim KJ; Kim JH; Park YB Int J Tuberc Lung Dis; 2014 Jun; 18(6):737-43. PubMed ID: 24903947 [TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Yu AP; Guérin A; de Leon DP; Ramakrishnan K; Wu EQ; Mocarski M; Blum SI; Setyawan J Respir Med; 2011 Dec; 105(12):1861-71. PubMed ID: 21807487 [TBL] [Abstract][Full Text] [Related]
13. [Costs of chronic obstructive pulmonary disease in patients treated in ambulatory care in Poland]. Jahnz-Różyk K; Targowski T; From S; Faluta T; Borowiec L Pneumonol Alergol Pol; 2011; 79(5):337-42. PubMed ID: 21861257 [TBL] [Abstract][Full Text] [Related]
14. Improvement in COPD management by access to asthma/COPD clinics in primary care: data from the observational PATHOS study. Lisspers K; Johansson G; Jansson C; Larsson K; Stratelis G; Hedegaard M; Ställberg B Respir Med; 2014 Sep; 108(9):1345-54. PubMed ID: 25002194 [TBL] [Abstract][Full Text] [Related]
15. Comparison of hospitalizations, emergency department visits, and costs in a historical cohort of Texas Medicaid patients with chronic obstructive pulmonary disease, by initial medication regimen. Rascati KL; Akazawa M; Johnsrud M; Stanford RH; Blanchette CM Clin Ther; 2007 Jun; 29(6):1203-13. PubMed ID: 17692734 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece. Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore. Lee KH; Phua J; Lim TK Respir Med; 2006 Dec; 100(12):2190-6. PubMed ID: 16635566 [TBL] [Abstract][Full Text] [Related]
18. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities. Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302 [TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD. Oba Y Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795 [TBL] [Abstract][Full Text] [Related]
20. Which long-acting bronchodilator is most cost-effective for the treatment of COPD? Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]